Clinical trial · Observational
FSRT Combined With TMZ for Large BMs: a PSM Study
Fractionated Stereotactic Radiotherapy Combined With Temozolomide for Large Brain Metastases: a Propensity-matched Study
NCT03338075CI-TRIAL-00030270completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A propensity- matched study was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | PROBABILISTIC | 0.70 |
| Chemotherapy | — | UNRESOLVED | — |
| Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fractionated stereotactic radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- CRT group
- description
- patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
- interventionNames
- Radiation: fractionated stereotactic radiotherapy
- label
- RT group
- description
- patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
- interventionNames
- Radiation: fractionated stereotactic radiotherapy
Primary outcomes (1)
- measure
- Local tumor control rate (LTCR)
- timeFrame
- 3 months after radiation
- description
- the control rate of treated lesions
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * (1) primary tumor was pathologically diagnosed and brain metastases were confirmed by gadolinium-enhanced magnetic resonance imaging (MRI) ; (2) age 18 years or older (3) KPS ≥60, or KPS ≥50 but symptomatically caused by BMs; (4) the large lesions haven't treated with surgery or SRT. Exclusion Criteria: * (1) KPS \<60 but not caused by BMs; (2) the large lesions have been treated with surgery or SRT.
References
Publications (0)
Data not yet available
No reference posted for this study.